One patient (0.3%) was treated with long-term enzyme replacement therapy for Pompe disease (alpha-glucosidase) and another one (0.3%) received brivaracetam and metformin for Lafora body disease, a type of rare, inherited and severe progressive myoclonic epilepsy. The gene discussed is GAA; the disease is progressive myoclonus epilepsy.